<DOC>
	<DOCNO>NCT01583816</DOCNO>
	<brief_summary>A Dose-Finding Study Resiquimod Evaluating Safety Efficacy Patients Multiple Actinic Keratosis Lesions</brief_summary>
	<brief_title>Dose-finding , Safety , Efficacy Trial Topical Resiquimod Patients With Multiple Actinic Keratosis Lesions</brief_title>
	<detailed_description>Prospective , randomize , partly blind , part placebo-controlled , multicenter dose-finding trial patient suffer AK . Patients observe efficacy , local tolerability safety . A total 14 site Switzerland Germany enrol male female patient 18 year age clinically diagnose AK lesion Patients randomize receive resiquimod gel ( Treatment Arms 1 , 2 , 3 , 4 , 5 ) matching vehicle ( Treatment Arms 1-Pla , 2-Pla , 3-Pla ) : Treatment Arms 1 , 2 3 : The patient randomly assign one three treatment group within group one randomly assign placebo patient every two treatment patient ( parallel-group randomization ; 2:1 active v placebo ) . Treatment Arms 4 5 : The patient randomly assign one two treatment group ( parallel-group randomization , 1:1 ) .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Signed informed consent Male nonpregnant , nonlactating female , â‰¥18 year A minimum 2 clinically diagnosed AKlesions within defined area ( 25 cm2 contiguous treatment area ) . One AKlesion must diameter least 6 mm ( indicator lesion ) AKlesions bald scalp , forehead face Known allergy hypersensitivity trial gel ingredient Dermatological disease condition might exacerbate resiquimod gel treatment may impair trial assessment Evidence unstable uncontrolled clinically significant medical condition , active infection , immunosuppression systemic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>Resiquimod</keyword>
</DOC>